nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2019-23-4-9-26nefr-1717Research ArticleПЕРЕДОВАЯ СТАТЬЯLEADING ARTICLEНефрология: фундаментальная и клиническаяNephrology: fundamental and clinicalhttps://orcid.org/0000-0001-7863-9080СмирновА. В.SmirnovA. V.

Смирнов Алексей Владимирович – профессор, доктор медицинских наук, директор научно-исследовательского института нефрологии, заведующий кафедрой пропедевтики внутренних болезней с клиникой.

197022, Санкт-Петербург, ул. Льва Толстого, д. 17, Тел.: (812)3386901

Alexey V. Smirnov - MD, PhD, DMedSci, Director of the Scientific Research Institute of Nephrology, Head of Department of Propaedeutics of Internal Diseases.

197022, St-Petersburg, L. Tolstoy st., 17, Phone: (812)3386901

smirnov@nephrolog.ruhttps://orcid.org/0000-0003-2075-5403НаточинЮ. В.NatochinYu. V.

Наточин Юрий Викторович - академик РАН, профессор, главный научный сотрудник Лаборатории физиологии почки.

YurijV. Natochin- MD, PhD, DSci, Acad. RAS, Chief Researcher of Laboratory of Renal physiology.

194223, St. Petersburg, M. Thorez pr., 44, Phone: (812)5523086

natochin1@mail.ruНаучно-исследовательский институт нефрологии, кафедра пропедевтики внутренних болезней с клиникой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаРоссияFirst Pavlov St-Petersburg State Medical University, Scientific Research Institute of NephrologyRussian FederationИнститут эволюционной физиологии и биохимии им. И.М. Сеченова, Российская академия наукРоссияI.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of SciencesRussian Federation201921062019234926Copyright © Смирнов А.В., Наточин Ю.В., 20192019Смирнов А.В., Наточин Ю.В.Smirnov A.V., Natochin Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1717

В настоящее время фундаментальная нефрология включает в себя многие разделы смежных наук, дающих новый импульс к пониманию механизмов функционирования почки на молекулярном уровне. Авторы статьи подчеркивают, что в основе функций почек лежат молекулярные системы, включающие разнообразные рецепторы, котранспортеры, насосы и ионные каналы, которые в конечном итоге обеспечивают гомеостаз организма. Фундаментальная нефрология, представляющая собой синтез физиологии и молекулярных ОМИКС-исследований, позволяет врачу более глубоко вникать в сущность патологических процессов, проводить диагностику болезней почек на доклиническом уровне. Тесная взаимосвязь фундаментальной и клинической нефрологии обеспечивает не только трансляцию научных достижений в практику, но и способствует персонификации терапии.

Currently, fundamental nephrology includes many sections of related sciences, giving a new way to understanding the mechanisms of kidney functioning at the molecular level. The authors of the article emphasize that the basis of kidney function comprises molecular systems, including a variety of receptors, cotransporters, pumps and ion channels, which ultimately provide the body's homeostasis. Fundamental nephrology, which is a synthesis of physiology and molecular OMIX-research, allows the doctor to more deeply delve into the essence of pathological processes, to diagnose kidney disease at the preclinical level. The close relationship between fundamental and clinical nephrology provides not only the translation of scientific advances into practice, but also contributes to the personification of therapy.

фундаментальная нефрологияклиническая нефрологияпатологический процессмолекулярные ОМИКС-исследованиятерапияfundamental nephrologyclinical nephrologypathological processmolecular OMIX-researchtherapyРабота выполнена в соответствии с госзаданиями: № 075-00776-19-00 по теме «Физиологические и биохимические механизмы гомеостаза и их эволюции» на 2019 г. и № ВНТИЦ АААА-А18-118070690071-8-«Иммуноморфологические факторы в оценке прогноза и эффективности лечения гломерулопатий» на 20182020 гг.ReferencesШик О. Нефрология практического врача. Гос. изд-во мед. лит., Прага, 1967, 341 с.Shik O. Nephrology practical doctor. State Publishing House of Medical Literature, Prague, 1967, 341 p. (In Russ.)Виктор З. Клиническая нефрология. Польское государственное медицинское издательство, Варшава, 1968, 344 с.Victor Z. Clinical nephrology. Polish state medical publishing house, Warsaw, 1968, 344 p. (In Russ.)Тареев ЕМ. Основы нефрологии. В 2-х томах. Медицина, М., 1972, 944 с.Tareev EM. Fundamentals of Nephrology. In 2volumes. Medicine, M., 1972, 944 p. (In Russ.)Hamburger J, Crosnier J, Grunfeld JP. Nephrology. Wiley-Frammarion, New York, 1979, 1393 p.Hamburger J, Crosnier J, Grunfeld JP. Nephrology. Wiley-Frammarion, New York, 1979, 1393 p.Пелещук АП. Практическая нефрология. Здоров'я, Киев, 1973, 384 с.Peleschuk AP Practical nephrology. Healthy, Kiev, 1973, 384 p. (In Russ.)Наточин ЮВ. Основы физиологии почки. Медицина, Л., 1982, 208 с.Natochin YuV. Basics of kidney physiology. Medicine, L. , 1982, 208 p. (In Russ.)Дворецкий ИХ. Латино-русский словарь. Русский язык, M. , 1986, 840 с.Dvoretskiy IKh. Latin-Russiandictionary. Russian language, M., 1986, 840 p. (In Russ.)Гальперин ИР. Большой англо-русский словарь в 2-х томах. Советская энциклопедия, М., 1972. Том 1, 823 с.Halperin IR. Large English-Russian dictionary in 2 volumes. Soviet Encyclopedia, M., 1972. Volume 1,823 p. (In Russ.)Kriz W, Bankir L, Bulger RE et al. A standart nomenclature for structures of the kidney. Kidney Int 1988;33(1):1-7Kriz W, Bankir L, Bulger RE et al. A standart nomenclature for structures of the kidney. Kidney Int 1988;33(1):1-7Smith HW. The Kidney: Structure and Function in Health and Disease. Oxford Univ. Press, New York, 1951,1049 p.Smith HW. The Kidney: Structure and Function in Health and Disease. Oxford Univ. Press, New York, 1951,1049 p.Brenner B (Еd.). Brenner & Rector's. The Kidney. 8 ed. Saunders Elsevier, Philadelphia, 2008 p.Brenner B (Еd.). Brenner & Rector's. The Kidney. 8 ed. Saunders Elsevier, Philadelphia, 2008 p.Alpern RJ, Hebert SC (Eds.). Seldin andGeibisch's. The Kidney. Physiology and pathophysiology. Elsevier, Academic Press, Amsterdam, 2008, 1427 p.Alpern RJ, Hebert SC (Eds.). Seldin andGeibisch's. The Kidney. Physiology and pathophysiology. Elsevier, Academic Press, Amsterdam, 2008, 1427 p.Рябов СИ. Нефрология. СпецЛит, СПб, 2000, 672 с.Ryabov SI. Nephrology. SpecLit, St. Petersburg, 2000, 672 p. (In Russ.)Шулутко БИ. Нефрология. Ренкор, СПб, 2002, 780 с.Shulutko BI. Nephrology. Rencore, St. Petersburg, 2002, 780 p. (In Russ.)Папаян АВ, Савенкова НД. Клиническая нефрология детского возраста. Левша, СПб, 2008, 600 с.Papayan AV, Savenkova ND. Clinical nephrology of childhood. Levsha, St. Petersburg, 2008, 600 p. (In Russ.)Папаян АВ, Стяжкина ИС. Неонатальная нефрология. Руководство. Питер, СПб, 2002, 238 с.Papayan AB, Styzkynna IP. Neonatal nephrology. Guide. Peter, St. Petersburg, 2002, 238 p. (In Russ.)Эрман МВ. Нефрология детского возраста: руководство для врачей. 2 изд. СпецЛит, СПб, 2010, 683 с.Erman MW. Nephrology of childhood: a guide for doctors. 2nd ed. SpecLit, St. Petersburg, 2010, 683 p. (In Russ.)Игнатова МС. Детская нефрология. Руководство для врачей. 3-изд. МИЯ, М., 2011, 696 с.Ignatov MS. Pediatric nephrology. A guide for doctors. 3rd ed. MIA, M., 2011, 696 p. (In Russ.)Наточин ЮВ. Нефрология и фундаментальная наука. Нефрология 2012;16(1):09-21. doi: 10.24884/1561-6274-2012-16-1-9-21Natochin YuV. Nephrology and Fundamental science. Nephrology (Saint-Petersburg) 2012;16(1):9-21. (In Russ.). doi: 10.24884/1561-6274-2012-16-1-9-21Kutina AV, Golosova DV, Marina AS et al. Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon-Like Peptide-1. J Neuroendocrinol 2016;28(4). doi: 10.1111/jne.12367Kutina AV, Golosova DV, Marina AS et al. Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon-Like Peptide-1. J Neuroendocrinol 2016;28(4). doi: 10.1111/jne.12367Наточин ЮВ, Голосова ДВ, Шахматова ЕИ. Новая функциональная роль окситоцина - участие в осморегуляции. Доклады Академии наук 2018;479(6):712-715Natochin YuV, Golosov DV, Shakhmatova EI. New functional role of oxytocin -participation in osmoregulation. Reports of the Academy of Sciences 2018;479(6):712-715. (In Russ.)Наточин ЮВ. Гомеостаз. Успехи физиол. наук 2017;48(4):3-15Natochin YuV. Homeostasis. Successes fiziol. sciences 2017;48(4):3-15. (In Russ.)Natochin YuV, Kuznetsova AA. Nocturnal enuresis: correction of renal function by desmopressin and diclofenac. Pediatr Nephrol 2000;14:42-47Natochin YuV, Kuznetsova AA. Nocturnal enuresis: correction of renal function by desmopressin and diclofenac. Pediatr Nephrol 2000;14:42-47Наточин ЮВ. Целостность.Журн. высш. нерв. деятельности 2018;68(6):775-787Natochin YuV. Integrity. Journal higher nerve activities 2018;68(6):775-787. (In Russ.)Шейман Дж. Патофизиология почки. Пер. с англ. Бином, М., 2019, 206 с.Sheiman J. Pathophysiology of the kidney. Transl. from English. Binom, M., 2019, 206 p. (In Russ.)Мухин НА. Нефрология: неотложные состояния. Эксмо, M., 2001, 288 с.Mukhin NA. Nephrology: emergency conditions. Eksmo, M., 2001,288 p. (In Russ.)Эмануэль ВЛ. Лабораторная диагностика заболеваний почек. Тверь, СПб, 2006, 248 с.Emanuel VL. Laboratory diagnosis of kidney disease. Tver, St. Petersburg, 2006, 248 p. (In Russ.)Рябов СИ, Наточин ЮВ. Функциональная нефрология. Лань, СПб, 1997, 304 с.Ryabov SI, Natochin YuV. Functional nephrology. Lan, St. Petersburg, 1997, 304 p. (In Russ.)Smith A, Galli M, L'Imperio V et al. MALDI-MS Imaging in the Study of Glomerulonephritis. Methods Mol Biol 2017;1618:85-94. doi: 10.1007/978-1-4939-7051-3_9Smith A, Galli M, L'Imperio V et al. MALDI-MS Imaging in the Study of Glomerulonephritis. Methods Mol Biol 2017;1618:85-94. doi: 10.1007/978-1-4939-7051-3_9Смирнов АВ. Системный подход к анализу кардиоренальных взаимоотношений как первый шаг на пути к нефрологии формата П4. Нефрология 2011;15(2):11-19. doi: 10.24884/1561-6274-2011-15-2-11-19Smirnov AV. Systematic approach to the analysis of cardio-renal relations as a first step towards nephrology P4 format. Nephrology (Saint-Petersburg) 2011;15(2):11-19. (In Russ.) doi: 10.24884/1561-6274-2011-15-2-11-19Баранов ВС. Геномика на пути к предиктивной медицине. Acta Naturaen2009;3:77-89Baranov VS. Genome Paths A Way to Personalized and Predictive Medicine. Acta Naturae 2009;3:77-89. (In Russ.)Баранов ВС, Баранова ЕВ. Геном человека, эпигенетика многофакторных болезней и персонифицированная медицина. Биосфера 2012;4(1):76-85Baranov VS, Baranova EV. Human genome, epigenetics of complex diseases and personalized medicine. Biosfera 2012;4(1):76-85. (In Russ.)Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329(5993):841-845. doi: 10.1126/science.1193032Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329(5993):841-845. doi: 10.1126/science.1193032Friedman DJ, Pollak MR. Genetics of kidney failure and the evolving story of APOL1. J Clin Invest 2011;121(9):3367-3374. doi: 10.1172/JCI46263Friedman DJ, Pollak MR. Genetics of kidney failure and the evolving story of APOL1. J Clin Invest 2011;121(9):3367-3374. doi: 10.1172/JCI46263Nelson GW, Freedman BI, Bowden DW et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet 2010;19(9):18051-815. doi: 10.1093/hmg/ddq039Nelson GW, Freedman BI, Bowden DW et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet 2010;19(9):18051-815. doi: 10.1093/hmg/ddq039Braun DA, Sadowski CE, Kohl S et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat Genet 2016;48(4):457-465. doi: 10.1038/ng.3512Braun DA, Sadowski CE, Kohl S et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat Genet 2016;48(4):457-465. doi: 10.1038/ng.3512Kottgen A, Hwang SJ, Larson MG et al. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 2010;21(2):3337-3344. doi: 10.1681/ASN.2009070725Kottgen A, Hwang SJ, Larson MG et al. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 2010;21(2):3337-3344. doi: 10.1681/ASN.2009070725Padmanabhan S, Melander O, Johnson T et al. Genomewide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010;6(10):e1001177. doi: 10.1371/journal.pgen.1001177Padmanabhan S, Melander O, Johnson T et al. Genomewide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010;6(10):e1001177. doi: 10.1371/journal.pgen.1001177Padmanabhan S, Graham L, Ferreri NR et al. Uromodulin, an emerging novel pathway for blood pressure regulation and hypertension. Hypertension 2014;64(5):918-923. doi: 10.1161/HYPERTENSIONAHA.114.03132Padmanabhan S, Graham L, Ferreri NR et al. Uromodulin, an emerging novel pathway for blood pressure regulation and hypertension. Hypertension 2014;64(5):918-923. doi: 10.1161/HYPERTENSIONAHA.114.03132Дедов ИИ, Тюльпаков АН, Чехонин ВП и др. Персонализированная медицина: современное состояние и перспективы. Вестник Российской академии медицинских наук 2012;67(12):4-12. doi: 10.15690/vramn.v67i12.474Dedov II, Tyul'pakov AI, Chekhonin VP et al. Personalized medicine: state-of-the-art and prospects. Annals of the Russian academy of medical sciences 2012;67(12):4-12. (In Russ.). doi: 10.15690/vramn.v67i12.474Gadegbeku CA, Gipson DS, Holzman LB et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. KidneyInt 2013;83(4):749-756. doi: 10.1038/ki.2012.428Gadegbeku CA, Gipson DS, Holzman LB et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. KidneyInt 2013;83(4):749-756. doi: 10.1038/ki.2012.428Cox SN, Sallustio F, Serino G et al. Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int 2012;82(5):548-560. doi: 10.1038/ki.2012.147Cox SN, Sallustio F, Serino G et al. Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int 2012;82(5):548-560. doi: 10.1038/ki.2012.147Cox SN, Sallustio F, Serino G et al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int 2010;78(4):396-407. doi: 10.1038/ki.2010.138Cox SN, Sallustio F, Serino G et al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int 2010;78(4):396-407. doi: 10.1038/ki.2010.138Banchereau R, Hong S, Cantarel B. Personalized Immu-nomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell 2016;165(3):551-565. doi: 10.1016/j.cell.2016.03.008Banchereau R, Hong S, Cantarel B. Personalized Immu-nomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell 2016;165(3):551-565. doi: 10.1016/j.cell.2016.03.008Brix SR, Stege G, Disteldorf E et al. CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN. J Am Soc Nephrol 2015;26(9):2105-2117. doi: 10.1681/ASN.2014040407Brix SR, Stege G, Disteldorf E et al. CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN. J Am Soc Nephrol 2015;26(9):2105-2117. doi: 10.1681/ASN.2014040407Ambros V. The functions of animal microRNAs. Nature 2004;431(7006):350-355. doi: 10.1038/nature02871Ambros V. The functions of animal microRNAs. Nature 2004;431(7006):350-355. doi: 10.1038/nature02871Бойко НВ, Голикова АЮ, Матишов ДГ, Тарасов ВА. Роль микроРНК в регуляции активности эукариот. Вестник Южного научного центра РАН 2011;7(3):69-78Boiko NV, Golikova AYu, Matishov DG, Tarasov VA. Role of miRNA in regulation of activity of genes in eukaryotes. Bulletin of the Southern Scientific Center of the Russian Academy of Sciences 2011; 7(3): 69-78. (In Russ.)Смирнов АВ, Карунная АВ, Зарайский МИ и др. Экспрессия микроРНК-21 в моче у пациентов с нефропатиями. Нефрология 2014;18(6):59-63Smirnov AV, Karunnaya AV, Zarayski MI et al. Urinary microRNA-21 expression in nephropathies. Nephrology (Saint-Petersburg) 2014;18(6):59-63. (In Russ.)Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004;1(1):47-53. doi: 10.1038/nmeth704Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004;1(1):47-53. doi: 10.1038/nmeth704Fan PC, Chen CC, Chen YC et al. MicroRNAs in acute kidney injury. Hum Genomics 2016;10(1):29. doi: 10.1186/s40246-016-0085-zFan PC, Chen CC, Chen YC et al. MicroRNAs in acute kidney injury. Hum Genomics 2016;10(1):29. doi: 10.1186/s40246-016-0085-zSaikumar J, Hoffmann D, Kim TM et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012;129(2):256-267. doi: 10.1093/toxsci/kfs210Saikumar J, Hoffmann D, Kim TM et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012;129(2):256-267. doi: 10.1093/toxsci/kfs210Lan YF, Chen HH, Lai PF et al. MicroRNA-494 reduces ATF3 expression and promotes AKI. J Am Soc Nephrol 2012;23(12):2012-23. doi: 10.1681/ASN.2012050438Lan YF, Chen HH, Lai PF et al. MicroRNA-494 reduces ATF3 expression and promotes AKI. J Am Soc Nephrol 2012;23(12):2012-23. doi: 10.1681/ASN.2012050438Serino G, Sallustio F, Cox SN et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol2012;23(5):814-824. doi: 10.1681/ASN.2011060567Serino G, Sallustio F, Cox SN et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol2012;23(5):814-824. doi: 10.1681/ASN.2011060567Szeto CC, Wang G, Ng JK et al. Urinary miRNA profile for the diagnosis of IgA nephropathy. BMC Nephrol 2019;20(1):77. doi: 10.1186/s12882-019-1267-4Szeto CC, Wang G, Ng JK et al. Urinary miRNA profile for the diagnosis of IgA nephropathy. BMC Nephrol 2019;20(1):77. doi: 10.1186/s12882-019-1267-4Anglicheau D, Sharma VK, Ding R et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 2009;106(13):5330-5335. doi: 10.1073/pnas.0813121106Anglicheau D, Sharma VK, Ding R et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 2009;106(13):5330-5335. doi: 10.1073/pnas.0813121106Khan Z, Suthanthiran M, Muthukumar T et al. MicroRNAs and Transplantation. Clin Lab Med 2019;39(1):125-143. doi: 10.1016/j.cll.2018.10.003Khan Z, Suthanthiran M, Muthukumar T et al. MicroRNAs and Transplantation. Clin Lab Med 2019;39(1):125-143. doi: 10.1016/j.cll.2018.10.003Сучков СВ, Гнатенко ДА, Костюшев ДС и др. Про-теомика как фундаментальный инструмент доклинического скрининга, верификации анализов и оценки применяемой терапии. Вестник Российской академии медицинских наук 2013;68(1):65-71. doi: 10.15690/vramn.v68i1.540Suchkov SV, Kostushev DS, Krynskii SA et al. Proteomics as a fundamental tool for subclinical screening, tests verification and assessment of applied therapy. Annals of the Russian academy of medical sciences 2013;68(1):65-71. (In Russ.) doi: 10.15690/vramn.v68i1.540Gold L, Ayers D, Bertino J et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010;5(12):e15004. doi: 10.1371/journal.pone.0015004Gold L, Ayers D, Bertino J et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010;5(12):e15004. doi: 10.1371/journal.pone.0015004Jain D, Green JA, Bastacky S et al. Membranoprolif-erative glomerulonephritis: the role for laser microdissection and mass spectrometry. Am J Kidney Dis 2014;63(2):324-328. doi: 10.1053/j.ajkd.2013.09.007Jain D, Green JA, Bastacky S et al. Membranoprolif-erative glomerulonephritis: the role for laser microdissection and mass spectrometry. Am J Kidney Dis 2014;63(2):324-328. doi: 10.1053/j.ajkd.2013.09.007Sethi S, Theis JD, Vrana JA et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 2013;8(6):915-921. doi: 10.2215/CJN.07030712Sethi S, Theis JD, Vrana JA et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 2013;8(6):915-921. doi: 10.2215/CJN.07030712Mariani LH, Pendergraft WF 3rd, Kretzler M. Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology. Clin J Am Soc Nephrol 2016;11(11):2054-2060. doi: 10.2215/CJN.13651215Mariani LH, Pendergraft WF 3rd, Kretzler M. Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology. Clin J Am Soc Nephrol 2016;11(11):2054-2060. doi: 10.2215/CJN.13651215Бобкова ИН, Кахсуруева ПА, Ставровская ЕВ, Филатова ЕЕ. Эволюция в понимании патогенеза идиопатической мембранозной нефропатии: от экспериментальных моделей к клинике. Альманах клинической медицины 2017;45(7):553-564. doi: 10.18786/2072-0505-2017-45-7-553-564Bobkova IN, Каkhsurueva PA, Stavrovskaya EV, Filatova EE. Evolution in the understanding of idiopathic membranous nephropathy pathogenesis: from experimental models to the clinic. Almanac of Clinical Medicine 2017;45(7):553-564. (In Russ.) doi: 10.18786/2072-0505-2017-45-7-553-564Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361(1):11-21. doi: 10.1056/NEJMoa0810457Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361(1):11-21. doi: 10.1056/NEJMoa0810457Stanescu HC, Arcos-Burgos M, Medlar A et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011;364(7):616-626. doi: 10.1056/NEJMoa1009742Stanescu HC, Arcos-Burgos M, Medlar A et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011;364(7):616-626. doi: 10.1056/NEJMoa1009742Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet 2015;385(9981):1983-1992. doi: 10.1016/S0140-6736(15)60731-0Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet 2015;385(9981):1983-1992. doi: 10.1016/S0140-6736(15)60731-0Добронравов ВА, Лапин СВ, Лазарева НМ и др. Циркулирующие антитела к рецептору фосфолипазы А2 при первичной мембранозной нефропатии. Нефрология 2012;16(4):39-44. doi: 10.24884/1561-6274-2012-16-4-39-44Dobronravov VA, Lapin SV, Lazareva NM et al. Circulating phospholipase A2 receptor antibodies in primary membranous nephropathy. Nephrology (Saint-Petersburg) 2012;16(4):39-44. (In Russ.) doi: 10.24884/1561-6274-2012-16-4-39-44Tomas NM, Beck LH Jr, Meyer-Schwesinger C et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371(24):2277-2287. doi: 10.1056/NEJMoa1409354Tomas NM, Beck LH Jr, Meyer-Schwesinger C et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371(24):2277-2287. doi: 10.1056/NEJMoa1409354Tomas NM, Hoxha E, Reinicke AT et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest 2016;126(7):2519-2532. doi: 10.1172/JCI85265Tomas NM, Hoxha E, Reinicke AT et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest 2016;126(7):2519-2532. doi: 10.1172/JCI85265Rovin BH, Klein JB. Proteomics and autoimmune kidney disease. Clin Immunol 2015;161(1):23-30. doi: 10.1016/j.clim.2015.04.021Rovin BH, Klein JB. Proteomics and autoimmune kidney disease. Clin Immunol 2015;161(1):23-30. doi: 10.1016/j.clim.2015.04.021Chen L, Su W, Chen H et al. Proteomics for Biomarker Identification and Clinical Application in Kidney Disease. Adv Clin Chem 2018;85:91-113. doi: 10.1016/bs.acc.2018.02.005Chen L, Su W, Chen H et al. Proteomics for Biomarker Identification and Clinical Application in Kidney Disease. Adv Clin Chem 2018;85:91-113. doi: 10.1016/bs.acc.2018.02.005Haubitz M, Wittke S, Weissinger EM et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005;67(6):2313-2320. doi: 10.1111/j.1523-1755.2005.00335.xHaubitz M, Wittke S, Weissinger EM et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005;67(6):2313-2320. doi: 10.1111/j.1523-1755.2005.00335.xVarghese SA, Powell TB, Budisavljevic MN et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol2007;18(3):913-922. doi: 10.1681/ASN.2006070767Varghese SA, Powell TB, Budisavljevic MN et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol2007;18(3):913-922. doi: 10.1681/ASN.2006070767Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67(6):2089-100. doi: 10.1111/j.1523-1755.2005.00365.xLevey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67(6):2089-100. doi: 10.1111/j.1523-1755.2005.00365.xMiller WG, Bruns DE, Hortin GL et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009;55(1):24-38. doi: 10.1373/clinchem.2008.106567Miller WG, Bruns DE, Hortin GL et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009;55(1):24-38. doi: 10.1373/clinchem.2008.106567Good DM, Zurbig P, Argiles A et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010;9(11):2424-2437. doi: 10.1074/mcp.M110.001917Good DM, Zurbig P, Argiles A et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010;9(11):2424-2437. doi: 10.1074/mcp.M110.001917Pontillo C, Mischak H. Urinary biomarkers to predict CKD: is the future in multi-marker panels? Nephrol Dial Transplant 2016;31(9):1373-1375. doi: 10.1093/ndt/gfv467Pontillo C, Mischak H. Urinary biomarkers to predict CKD: is the future in multi-marker panels? Nephrol Dial Transplant 2016;31(9):1373-1375. doi: 10.1093/ndt/gfv467Siwy J, Zurbig P, Argiles A et al. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrol Dial Transplant 2017;32(12):2079-2089. doi: 10.1093/ndt/gfw337Siwy J, Zurbig P, Argiles A et al. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrol Dial Transplant 2017;32(12):2079-2089. doi: 10.1093/ndt/gfw337Mischak H. Pro:urine proteomics as a liquid kidney biopsy: no more kidney punctures! Nephrol Dial Transplant 2015;30(4):532-537. doi: 10.1093/ndt/gfv046Mischak H. Pro:urine proteomics as a liquid kidney biopsy: no more kidney punctures! Nephrol Dial Transplant 2015;30(4):532-537. doi: 10.1093/ndt/gfv046Parikh CR, Mansour SG. Perspective on Clinical Application of Biomarkers in AKI. J Am Soc Nephrol 2017;28(6):1677-1685. doi: 10.1681/ASN.2016101127Parikh CR, Mansour SG. Perspective on Clinical Application of Biomarkers in AKI. J Am Soc Nephrol 2017;28(6):1677-1685. doi: 10.1681/ASN.2016101127Добронравов ВА, Смирнов КА, Афанасьев БВ и др. Острое повреждение почек и тубулярные биомаркеры при трансплантации гемопоэтических стволовых клеток. Терапевтический архив 2016;88(6):14-20. DOI: 10.17116/ terarkh201688614-20Dobronravov VA, Smirnov KA, Afanasiev BV et al. Acute kidney injury and tubular biomarkers after hematopoietic stem cell transplantation. Therapeutic archive 2016;88(6):14-20. (In Russ.) DOI: 10.17116/terarkh201688614-20Пролетов ЯЮ, Саганова ЕС, Галкина ОВ и др. Роль некоторых биомаркеров в оценке характера повреждения почек у пациентов с первичными гломерулопатиями. Нефрология 2013;17(1):60-69. doi: 10.24884/1561-6274-2013-17-1-60-69Proletov II, Saganova ES, Galkina OV et al. The role of several biomarkers in estimation of kidney injury in patients with primary glomwrulopathies. Nephrology (Saint-Petersburg) 2013;17(1):60-69. (In Russ.) doi: 10.24884/1561-6274-2013-17-1-60-69Rysz J, Gluba-Brzozka A, Franczyk B et al. Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. Int J Mol Sci 2017;18(8). pii:E1702. doi: 10.3390/ijms18081702Rysz J, Gluba-Brzozka A, Franczyk B et al. Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. Int J Mol Sci 2017;18(8). pii:E1702. doi: 10.3390/ijms18081702German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 2005;1(1):3-9. doi: 10.1007/s11306-005-1102-8German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 2005;1(1):3-9. doi: 10.1007/s11306-005-1102-8Pauling L, Robinson AB, Teranishi R, Cary P Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci U S A 1971;68(10):2374-2376. doi: 10.1073/pnas.68.10.2374Pauling L, Robinson AB, Teranishi R, Cary P Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci U S A 1971;68(10):2374-2376. doi: 10.1073/pnas.68.10.2374Xiao JF, Zhou B, Ressom HW. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends Analyt Chem 2012;32:1-14. doi: 10.1016/j.trac.2011.08.009Xiao JF, Zhou B, Ressom HW. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends Analyt Chem 2012;32:1-14. doi: 10.1016/j.trac.2011.08.009Wishart DS, Tzur D, Knox C et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007;35(Database issue):D521-D526. doi: 10.1093/nar/gkl923Wishart DS, Tzur D, Knox C et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007;35(Database issue):D521-D526. doi: 10.1093/nar/gkl923Wishart DS, Feunang YD, Marcu A et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res 2018;46(D1):D608-D617. doi: 10.1093/nar/gkx1089Wishart DS, Feunang YD, Marcu A et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res 2018;46(D1):D608-D617. doi: 10.1093/nar/gkx1089Фурина РР, Митракова НН, Рыжков ВЛ, Сафиуллин ИК. Метаболомические исследования в медицине. Казанский медицинский журнал 2014;95(1):1-6Furina RR, Mitrakova NN, Ryzhkov VL, Safiullin IK. Metabolomic research in medicine. Kazan Medical Journal 2014;95(1):1-6. (In Russ.)Abbiss H, Maker GL, Trengove RD. Metabolomics Approaches for the Diagnosis and Understanding of Kidney Diseases. Metabolites 2019;9(2). pii:E34. doi: 10.3390/metabo9020034Abbiss H, Maker GL, Trengove RD. Metabolomics Approaches for the Diagnosis and Understanding of Kidney Diseases. Metabolites 2019;9(2). pii:E34. doi: 10.3390/metabo9020034Wang C, Feng Y Wang M et al. Volatile Organic Metabolites Identify Patients with Mesangial Proliferative Glomerulonephritis, IgA Nephropathy and Normal Controls. Sci Rep 2015;5:14744. doi: 10.1038/srep14744Wang C, Feng Y Wang M et al. Volatile Organic Metabolites Identify Patients with Mesangial Proliferative Glomerulonephritis, IgA Nephropathy and Normal Controls. Sci Rep 2015;5:14744. doi: 10.1038/srep14744Kalantari S, Nafar M, Samavat S, Parvin M. 1 H NMR-based metabolomics study for identifying urinary biomarkers and perturbed metabolic pathways associated with severity of IgA nephropathy: a pilot study. Magn Reson Chem 2017;55(8):693-699. doi: 10.1002/mrc.4573Kalantari S, Nafar M, Samavat S, Parvin M. 1 H NMR-based metabolomics study for identifying urinary biomarkers and perturbed metabolic pathways associated with severity of IgA nephropathy: a pilot study. Magn Reson Chem 2017;55(8):693-699. doi: 10.1002/mrc.4573Taherkhani A, Kalantari S, Arefi Oskouie A et al. Network analysis of membranous glomerulonephritis based on metabolomics data. Mol Med Rep 2018;18(5):4197-4212. doi: 10.3892/mmr.2018.9477Taherkhani A, Kalantari S, Arefi Oskouie A et al. Network analysis of membranous glomerulonephritis based on metabolomics data. Mol Med Rep 2018;18(5):4197-4212. doi: 10.3892/mmr.2018.9477Guleria A, Pratap A, Dubey D et al. NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis. Sci Rep 2016;6:35309. doi: 10.1038/srep35309Guleria A, Pratap A, Dubey D et al. NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis. Sci Rep 2016;6:35309. doi: 10.1038/srep35309Li J, Xie XW, Zhou H et al. Metabolic profiling reveals new serum biomarkers of lupus nephritis. Lupus 2017;26(11):1166-1173. doi: 10.1177/0961203Li J, Xie XW, Zhou H et al. Metabolic profiling reveals new serum biomarkers of lupus nephritis. Lupus 2017;26(11):1166-1173. doi: 10.1177/0961203Боткин СП. Курс клиники внутренних болезней и клинические лекции. В 2 томах. Медгиз, М., 1950. Том 1,364 с.Botkin SP Course of Internal Medicine Clinic and Clinical Lectures. In 2 volumes. Medgiz, M., 1950. Vol. 1,364 p. (In Russ.)Смольянинов АВ, Хмельницкий ОК, Петленко ВП. Теоретические основы морфологического диагноза. СПбМАПО, СПб., 1995:13 [Smolyaninov AV, Khmelnitsky OK, Petlenko VP. The theoretical basis of morphological diagnosis. SPbMAPO, SPb., 1995:13 (In Russ.)]Smolyaninov AV, Khmelnitsky OK, Petlenko VP. The theoretical basis of morphological diagnosis. SPbMAPO, SPb., 1995:13 (In Russ.)Эйнштейн А. Цит. по: Марков М. О единстве и многообразии форм материи в физической картине мира. Наука и жизнь 1982;7:3-10Einstein A. Cit. by: Markov M. On the unity and diversity of forms of matter in the physical picture of the world. Science and Life 1982;7:3-1. (In Russ.)Орбели ИА. Избранные труды. В 2-х томах. Л., М., 1961. Том 1,61 с.Orbeli IA. Selected Works. In 2 volumes. L., M., 1961. Volume 1,61 p. (In Russ.)Смольянинов АВ, Хмельницкий ОК, Петленко ВП. Теоретические основы морфологического диагноза. СПбМАПО, СПб, 1995:12Smolyaninov AV, Khmelnitsky OK, Petlenko VP The theoretical basis of morphological diagnosis. SPbMAPO, SPb, 1995:12. (In Russ.)Panda SC. Medicine: science or art? Mens Sana Monogr 2006;4(1):127-138. doi: 10.4103/0973-1229.27610Panda SC. Medicine: science or art? Mens Sana Monogr 2006;4(1):127-138. doi: 10.4103/0973-1229.27610Разумов АС. Медицина XXI века: Биочипы. Медицина в Кузбасе 2009;2:3-11Razumov AS. Medicine of the 21st century: Biochips. Medicine in Kuzbass 2009;2:3-11. (In Russ.)Volhard F, Fahr Th. Брайтова болезнь почек. Перевод с нем. под редакцией Готье ЭВ, Мелких СМ. Белтрестпечать, Минск, 1923, 343 с.Volhard F, Fahr Th. Брайтова болезнь почек. Перевод с нем. под редакцией Готье ЭВ, Мелких СМ. Белтрестпечать, Минск, 1923, 343 с. [Volhard F, Fahr Th. Bright's renal diseases. Translation from German, edited by Got'e EV, Melkih SM. Beltrest-pechat', Minsk, 1923, 343 p. (In Russ.)]Pal A, Kaskel F. History of Nephrotic Syndrome and Evolution of its Treatment. Front Pediatr 2016;4:56. doi: 10.3389/fped.2016.00056Pal A, Kaskel F. History of Nephrotic Syndrome and Evolution of its Treatment. Front Pediatr 2016;4:56. doi: 10.3389/fped.2016.00056Тареев ЕМ. Нефриты. Медгиз, М., 1958, 667 с.Tareev EM. Nephritis. Medgiz, M., 1958, 667 p. (In Russ.)Смирнов АВ, Добронравов ВА, Сиповский ВГ и др. Клинические рекомендации по диагностике, лечению и прогнозу мембранопролиферативного гломерулонефрита. Нефрология 2014;18(6):82-93Smirnov AV, Dobronravov VA, Sipovskii VG et al. Clinical practice guideline for diagnostics, treatment and prognosis of membranoproliferative glomerulonephritis. Nephrology (Saint-Petersburg) 2014;18(6):82-93. (In Russ.)Сети C, Фервенца ФК. Стандартизированный подход к классификации и морфологическому описанию гломерулонефрита. Нефрология 2019;23(4)Sethi S, Fervenza FC. Standardized classification and reporting of glomerulonephritis. Nephrology (Saint-Petersburg) 2019;23(4):in print. (In Rus.)

The authors declare that there are no conflicts of interest present.